$118.10
+0.93 (+0.79%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where CORT is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
67 interventional · 6 observational · 15 with posted results
Held by 13 tracked-famous managers (RENAISSANCE TECHNOLOGIES LLC, AQR CAPITAL MANAGEMENT LLC, D. E. Shaw & Co., Inc., TWO SIGMA INVESTMENTS, LP, MILLENNIUM MANAGEMENT LLC, +8 more) · FINRA short interest 6.4 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 15 sells · government filings 180d: 0 congress / 1 executive
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic AdenocarcinomaNCT07259317Percent of Patients who Experience Dose Limiting Toxicity (DLT) (Part 1)Open-label · Treatment | Phase 2 | Recruiting | Drug: Relacorilant, Nab-paclitaxel, Gemcitabine | Adenocarcinoma, Carcinoma, Pancreatic Ductal | 80 | Sep 2027 | ≤ 407 d | 2026-08-18 |
| Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing SyndromeNCT03604198Long-term safety of relacorilantOpen-label · Treatment | Phase 2 | Active, not recruiting | Drug: relacorilant | Cushing Syndrome | 125 | Dec 2026 | ≤ 134 d | 2026-08-13 |
| Dazucorilant in Patients With Amyotrophic Lateral SclerosisNCT05407324Change from Baseline to Week 24 in the ALS Functional Rating Scale-Revised (ALSFRS-R) total score.Randomized · Triple-masked · Treatment | Phase 2 | Recruiting | Drug: Dazucorilant 300 mg, Dazucorilant 150 mg, Dazucorilant · Other: Placebo | Amyotrophic Lateral Sclerosis | 279 | Oct 2026 | ≤ 73 d | 2026-06-16 |
| Evaluating the Pharmacokinetics and Safety of MiricorilantNCT07553663Assessment of miricorilant PK parametersOpen-label · Treatment | Phase 1 | Recruiting | Drug: Miricorilant | Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis, Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Non-alcoholic Fatty Liver Disease (NAFLD) | 15 | 2026-10-30 | in 72 d | 2026-05-26 |
| A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)NCT06108219Percent relative change from Baseline in liver-fat content assessed by MRI-PDFF (Cohort A and Cohort B)Randomized · Quadruple-masked · Treatment | Phase 2 | Active, not recruiting | Drug: Miricorilant (Cohort A), Placebo (Cohort A), Miricorilant (Cohort B), Placebo (Cohort B) | Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-associated Steatohepatitis (MASH) | 175 | Sep 2026 | ≤ 42 d | 2026-05-08 |
| Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid MalignanciesNCT07276373Number of Patients With 1 or More Adverse EventNon-randomized · Open-label · Treatment | Phase 1/2 | Recruiting | Drug: Nenocorilant 200 mg, Nenocorilant 300 mg, Nenocorilant 400 mg, Nivolumab | Neoplasms | 50 | Sep 2026 | ≤ 42 d | 2026-08-19 |
| Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological CancersNCT06906341Progression-Free Survival (PFS)Non-randomized · Open-label · Treatment | Phase 2 | Recruiting | Drug: Relacorilant 150 mg once daily (QD), Nab-paclitaxel 80 mg/m^2, Bevacizumab 10 mg/kg | Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms, Endometrial Cancer | 270 | Aug 2026 | ≤ 12 d | 2026-07-16 |
| Evaluation of Miricorilant on Liver Fat in Patients With MASLDNCT06947304Change in fasting hepatic lipogenesis after 6 weeks of treatmentOpen-label · Treatment | Phase 1 | Active, not recruiting | Drug: Miricorilant | Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-Associated Steatohepatitis (MASH), Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Non-alcoholic Fatty Liver Disease (NAFLD) | 9 | Aug 2026 | ≤ 12 d | 2026-07-30 |
| Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube CancerNCT05257408Progression-free Survival as Assessed by BICRRandomized · Open-label · Treatment | Phase 3 | Active, not recruiting | Drug: Nab-paclitaxel 80 mg/m^2, Relacorilant 150 mg once daily (QD), Nab-paclitaxel 100 mg/m^2 | Ovarian Neoplasm, Fallopian Tube Neoplasms, Peritoneal Neoplasms | 381 | 2025-03-24actual | — | 2025-04-16 |
| Study Evaluating the Bioavailability of Miricorilant With Optional Food Effect Assessment in Healthy Adult SubjectsNCT07240116Time of Maximum Observed Concentration (Tmax) of MiricorilantRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: Miricorilant Treatment A, Miricorilant Treatment B, Miricorilant Treatment C, Miricorilant Treatment D | Healthy | 18 | 2026-03-03actual | — | 2026-04-13 |
| Study of the Prevalence of Endogenous Hypercortisolism in Patients With Resistant Hypertension (MOMENTUM)NCT06829537observationalTo assess the prevalence of endogenous hypercortisolism in a population with resistant hypertension. | — | Completed | — | Resistant Hypertension, Hypercortisolism | 1,143 | 2025-12-08actual | — | 2026-02-17 |
| Effects of Hepatic Impairment on the Pharmacokinetics of DazucorilantNCT06928779Area under the concentration-time curve from time zero to the last non-zero concentration (AUC0-t) of dazucorilantNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Dazucorilant | Hepatic Impairment | 19 | 2024-12-09actual | — | 2025-04-15 |
| Study to Determine the Prevalence of Hypercortisolism in Patients With Type 2 Diabetes and Treatment With Korlym® (Mifepristone) (CATALYST)NCT05772169Part 1 Prevalence Phase: Prevalence of HypercortisolismRandomized · Triple-masked · Treatment | Phase 4 | Completed | Drug: Mifepristone 300 MG [Korlym], Placebo for mifepristone | Hypercortisolism, Diabetes Mellitus, Type 2 | 1,113 | 2024-11-19actual | — | 2025-01-20 |
| A Study of the Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal AdenomasNCT04308590results2025-08-03Change in Average 24-hour SBPRandomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Relacorilant · Other: Placebo | Hypercortisolism | 137 | 2024-09-19actual | — | 2025-09-04 |
| Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of MiricorilantNCT05553470Area under the Concentration-Time Curve (AUC) from Time Zero to the Last Non-Zero Concentration (AUC 0-t)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Miricorilant | Non-alcoholic Steatohepatitis (NASH) | 19 | 2024-09-13actual | — | 2025-03-30 |
| Impact of Itraconazole on the Pharmacokinetics and Safety of Dazucorilant in Healthy, Adult ParticipantsNCT06495944Maximum observed plasma concentration (Cmax) of dazucorilantOpen-label · Treatment | Phase 1 | Completed | Drug: Dazucorilant, Itraconazole | Healthy Adults | 21 | 2024-08-02actual | — | 2025-07-01 |
| A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing SyndromeNCT03697109results2025-04-24Number of Patients With Loss of Response With Respect to Hypertension During the RW Phase.Randomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Relacorilant · Other: Placebo | Cushing Syndrome | 152 | 2024-04-08actual | — | 2025-07-16 |
| A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)NCT05117489Relative change from Baseline in liver-fat content assessed by MRI-PDFF compared to Baseline.Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Miricorilant 150 mg, Miricorilant 100 mg, Miricorilant 50 mg, Miricorilant 10 mg | Nonalcoholic Steatohepatitis (NASH) | 70 | 2024-01-29actual | — | 2024-08-19 |
| Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produces Too Much Stress Hormone (Cortisol)NCT04373265Dose-limiting Toxicity (DLT)Open-label · Treatment | Phase 1 | Completed | Drug: Relacorilant, Pembrolizumab | Adrenocortical Carcinoma | 15 | 2023-10-17actual | — | 2024-02-23 |
| A Sub Study of the Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)NCT05320146observationalChange in liver-fat content assessed by MRI-PDFF after the last dose of study drug. | — | Completed | Other: MRI-PDFF | Nonalcoholic Steatohepatitis (NASH) | 22 | 2023-07-18actual | — | 2024-08-19 |
| Study to Evaluate the Effects of a Cytochrome P450 2C19 Inhibitor on the Pharmacokinetics of MiricorilantNCT05712265Maximum observed plasma concentration of miricorilant (Cmax)Open-label · Treatment | Phase 1 | Completed | Drug: Miricorilant, Fluvoxamine | Antipsychotic Induced Weight Gain, Non-alcoholic Steatohepatitis (NASH) | 26 | 2023-02-23actual | — | 2023-03-22 |
| Single and Multiple Ascending Dose Study of CORT125236 in Healthy ParticipantsNCT05003713Number of Participants with One or More Adverse EventsRandomized · Double-masked · Basic science | Phase 1 | Completed | Drug: CORT125236, Placebo matching CORT125236, Prednisone | Healthy | 82 | 2023-02-03actual | — | 2023-03-22 |
| A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Obese Adult Patients With Schizophrenia While Taking Antipsychotic Medications (GRATITUDE II)NCT04524403results2024-06-13Change From Baseline in Body WeightRandomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Miricorlilant, Miricorlilant, Placebo | Antipsychotic-induced Weight Gain (AIWG) | 150 | 2022-07-29actual | — | 2024-06-13 |
| Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-glycoprotein Substrate Dabigatran Etexilate in Healthy ParticipantsNCT05347979Maximum Observed Plasma Concentration (Cmax) of Dabigatran When Administered With and Without RelacorilantOpen-label · Treatment | Phase 1 | Completed | Drug: Dabigatran Etexilate, Relacorilant | Cushing Syndrome, Neoplasms | 30 | 2022-07-19actual | — | 2023-02-09 |
| A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adults With Schizophrenia or Bipolar Disorder Treated With Antipsychotic MedicationsNCT03818256results2024-09-19Change From Baseline in Body Weight at Week 12 for 600 mg Miricorilant Versus PlaceboRandomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Miricorilant, Placebo | Antipsychotic-induced Weight Gain (AIWG) | 71 | 2022-06-17actual | — | 2024-09-19 |
| Single and Multiple Ascending Dose Study of CORT125329 in Healthy ParticipantsNCT04672512Percentage of Participants with One or More Adverse EventsRandomized · Double-masked · Basic science | Phase 1 | Completed | Drug: CORT125329 lipid capsule formulation, Placebo, Prednisone | Healthy | 115 | 2022-01-17actual | — | 2022-02-09 |
| Study to Evaluate Exicorilant (CORT125281) in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate CancerNCT03437941results2026-05-15Number of Patients With One or More Dose-Limiting Toxicity (DLT)Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Terminatedsponsor's stated reason: The level of benefit observed did not justify enrolling patients in the Dose Expansion phase of the study. | Drug: Exicorilant, Enzalutamide, Placebo | Metastatic Castration-Resistant Prostate Cancer | 39 | 2021-10-13actual | — | 2026-05-15 |
| Safety, Tolerability, and Pharmacokinetic Study of CORT113176 in Healthy ParticipantsNCT04994743Number of Participants with One or More Adverse EventsRandomized · Double-masked · Treatment | Phase 1 | Completed | Drug: CORT113176, Placebo matching CORT113176 | Healthy Adults | 16 | 2021-09-30actual | — | 2021-10-11 |
| Single Dose Absorption, Distribution, Metabolism, and Excretion Study of [14C]-CORT113176 in Healthy Male ParticipantsNCT04990310Mass Balance Recovery in Excreta After a Single Dose of [14C]-CORT113176Open-label · Basic science | Phase 1 | Completed | Drug: [14C]-CORT113176 | Healthy | 6 | 2021-09-20actual | — | 2021-11-24 |
| Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal AdenocarcinomaNCT04329949results2023-11-18Objective Response Rate (ORR) Per Blinded Independent Central Review (BICR)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Terminatedsponsor's stated reason: The independent data monitoring committee found no safety issues, however the observed response rate did not meet the predefined threshold for continuing the study. The study was terminated by the Sponsor. | Drug: Relacorilant, 100 mg and 25 mg, Nab-paclitaxel | Metastatic Pancreatic Ductal Adenocarcinoma | 43 | 2021-08-23actual | — | 2023-11-18 |
| T/QT Study to Investigate the Effect of Relacorilant on Cardiac Repolarization in Healthy VolunteersNCT04795479Placebo-corrected Change from Baseline in Cardiac QT Interval Corrected by Fridericia's Formula (QTcF)Randomized · Double-masked · Treatment | Phase 1 | Completed | Drug: Relacorilant, Placebo to relacorilant, Moxifloxacin | Healthy | 36 | 2021-05-17actual | — | 2021-09-14 |
| Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Participants With Presumed Nonalcoholic Steatohepatitis (NASH)NCT03823703results2022-08-31Relative Change From Baseline in Liver Fat Content Assessed by Magnetic Resonance Imaging-Proton Density Fat FractionRandomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Suspended by sponsor, pending investigation of abnormal laboratory values in patients with NASH | Drug: Miricorilant, Placebo | Nonalcoholic Steatohepatitis (NASH) | 12 | 2021-04-05actual | — | 2022-08-31 |
| Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal CancerNCT03776812results2025-04-30Progression-free Survival (PFS)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Relacorilant, Nab-paclitaxel | Recurrent Ovarian Cancer, Recurrent Fallopian Tube Carcinoma, Recurrent Primary Peritoneal Carcinoma | 178 | 2021-03-16actual | — | 2025-10-07 |
| A Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of RelacorilantNCT06094725Maximum concentration of plasma relacorilant during the dosing interval (Cmax)Non-randomized · Open-label · Other | Phase 1 | Completed | Drug: Relacorilant | Hepatic Impairment | 30 | 2020-12-14actual | — | 2023-10-23 |
| A Study to Evaluate the Effect of Food on the Oral Bioavailability of Relacorilant in Healthy SubjectsNCT06094738Area under the concentration-time curve from time zero to the last observed concentration of plasma relacorilant (AUC0-t)Randomized · Open-label · Other | Phase 1 | Completed | Drug: Relacorilant under fasted conditions, Relacorilant after a high-fat meal, Relacorilant after a low-fat meal | Healthy | 30 | 2020-11-16actual | — | 2023-10-23 |
| Single and Multiple Ascending Dose Study of CORT113176 in Healthy ParticipantsNCT04249323Number of Participants with One or More Adverse EventsRandomized · Double-masked · Basic science | Phase 1 | Completed | Drug: CORT113176 Lipid Capsule Formulation, Placebo matching CORT113176 Lipid Capsule Formulation, Prednisone | Healthy Adults | 110 | 2020-10-15actual | — | 2022-02-01 |
| Single and Multiple Dose Study of Miricorilant (CORT118335) Tablet Formulations in Healthy ParticipantsNCT04672499Percentage of Participants with One or More Adverse EventsRandomized · Double-masked · Treatment | Phase 1 | Completed | Drug: Miricorilant 300 mg tablets, Miricorilant 150 mg tablets, Placebo 150 mg tablets | Healthy | 36 | 2020-09-07actual | — | 2020-12-17 |
| Study to Evaluate Relacorilant (CORT125134) in Combination With Nab-paclitaxel in Participants With Solid TumorsNCT02762981results2022-12-06Number of Participants With Dose-limiting ToxicityOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Drug: Relacorilant with nab-paclitaxel | Solid Tumors | 85 | 2020-05-12actual | — | 2022-12-06 |
| The Effect of CORT118335 on Olanzapine-Induced Weight GainNCT03877562Mean Change from Baseline in Body WeightRandomized · Double-masked · Prevention | Phase 1 | Completed | Drug: Olanzapine, CORT118335, Placebo | Antipsychotic-induced Weight Gain | 96 | 2020-03-13actual | — | 2020-04-28 |
| Study in Healthy Subjects to Determine the Effect of an Inhibitor on Exposure to Relacorilant and Its MetabolitesNCT03512548Area under plasma concentration-time curve up to the last quantifiable sample (AUC0-tz)Non-randomized · Open-label · Other | Phase 1 | Completed | Drug: Relacorilant 350mg, Itraconazole, Relacorilant 300mg | Healthy | 52 | 2019-07-29actual | — | 2020-03-24 |
| Absolute Bioavailability and Metabolism Study of CORT118335 in Healthy Male ParticipantsNCT03878264Absolute Oral Bioavailability (F) of CORT118335Non-randomized · Open-label · Basic science | Phase 1 | Completed | Drug: CORT118335 Oral, 14C-CORT118335 intravenous, 14C-CORT118335 oral | Healthy | 12 | 2019-03-24actual | — | 2019-06-11 |
| First-in-human Study in Healthy SubjectsNCT03315338Adverse Events (AEs)Randomized · Triple-masked · Basic science | Phase 1 | Completed | Drug: CORT118335, 25 mg, Prednisone Oral Tablet, Glucose, Placebo oral suspension, CORT118335, 75mg, CORT118335, 225mg, CORT118335, 675mg, CORT118335, 600mg, CORT118335, 630mg, CORT118335, 375mg, CORT118335, 100mg, CORT118335, 300mg, CORT118335, 900mg, CORT118335, 150mg, CORT118335, 1500mg, Placebo oral capsule, CORT118335, dose to be determined | Healthy | 143 | 2019-02-22actual | — | 2019-05-24 |
| Mass Balance Recovery and Metabolite Profile of CORT125281 in Healthy Male ParticipantsNCT03877952Mass Balance Recovery in Excreta After a Single Oral Dose of 14C-CORT125281Open-label · Basic science | Phase 1 | Completed | Drug: 14C-CORT125281 | Healthy | 6 | 2018-11-01actual | — | 2019-03-18 |
| Biomarker Expression in Patients With ACTH-Dependent Cushing's Syndrome Before and After SurgeryNCT02922257observationalGene expression levels | — | Completed | — | Cushing's Syndrome | 26 | 2018-10-30actual | — | 2019-01-24 |
| Study to Evaluate CORT125134 in Participants With Cushing's SyndromeNCT02804750results2019-09-25Percentage of Participants With One or More Adverse EventsNon-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: CORT125134 | Cushing's Syndrome | 35 | Sep 2018actual | — | 2019-10-15 |
| A Study to Determine the Relative Bioavailability of Two New Relacorilant Capsule VariantsNCT03540836Area under plasma concentration-time curve up to the last quantifiable sample (AUC0-tz)Randomized · Open-label · Other | Phase 1 | Completed | Drug: Relacorilant (3x100 mg softgel capsules), Relacorilant (3x100 mg hard-shell capsules), Relacorilant (6x50mg hard-shell capsules) | Healthy | 30 | 2018-07-16actual | — | 2018-09-07 |
| CORT125281 Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD)NCT03335956Adverse Events (AEs)Randomized · Triple-masked · Basic science | Phase 1 | Completed | Drug: CORT125281, 40mg, fasted, Prednisone 25mg, fasted, Placebo oral capsule, fasted, Pioglitazone 15mg Tablet, Placebo oral capsule, fed, Prednisone 25mg, fed, CORT125281, 120mg, fasted, CORT125281, 360mg, fasted, CORT125281, 720mg, fasted, CORT125281, 360mg, fed, CORT125281, 360mg, CORT125281, 120mg, CORT125281, 180mg, CORT125281, 240mg, CORT125281, 360mg, Placebo oral capsule, Placebo oral capsule, Placebo oral capsule | Healthy | 48 | 2018-05-31actual | — | 2018-07-26 |
| Study in Healthy Subjects to Determine the Effect of Relacorilant on Exposure to Probe Substrates for Cytochrome P450sNCT03457597Area under plasma concentration-time curve up to the last quantifiable sample (AUC0-tz)Non-randomized · Open-label · Other | Phase 1 | Completed | Drug: Midazolam hydrochloride, Metoprolol tartrate, Pioglitazone hydrochloride, Tolbutamide, Omeprazole, Relacorilant | Healthy | 27 | 2018-04-15actual | — | 2018-05-17 |
| Relacorilant Food Effect Study in Healthy SubjectsNCT03442621Area under plasma concentration-time curve up to the last quantifiable sample (AUC0-tz)Randomized · Open-label · Other | Phase 1 | Completed | Drug: Relacorilant Fasted, Relacorilant with a high fat breakfast, Relacorilant with a moderate breakfast | Healthy, Food-drug Interaction | 30 | 2018-02-28actual | — | 2018-05-17 |
| Retrospective Chart Review Study of Pediatric Patients Treated With Korlym for Cushing SyndromeNCT03379363observationalDrug utilization patterns as assessed by chart review | — | Terminatedsponsor's stated reason: Insufficient number of patients | — | Hypercortisolism, Cushing Syndrome | 2 | 2018-02-12actual | — | 2019-07-30 |
| Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid TumorsNCT02014337Determine the MTD and recommended Phase 2 dose (RP2D) of the combination of mifepristone and eribulin in patients with metastatic or locally advanced unresectable breast or other specified solid tumors.Open-label · Treatment | Phase 1 | Completed | Drug: Mifepristone and Eribulin in combination | Breast Cancer, Ovarian Epithelial Cancer Recurrent, Sarcoma, Non-small Cell Lung Cancer, Carcinoma, Transitional Cell, Prostate Cancer, Prostatic Neoplasms | 37 | Dec 2017actual | — | 2018-01-17 |
| Mifepristone Drug-Drug Interaction Study With CYP3A InhibitorNCT03259542Cmax of mifepristone at Day 42 compared to Day 28Open-label · Other | Phase 1 | Completed | Drug: Mifepristone 300 MG, Itraconazole 100 MG | Drug Interaction Potentiation, Healthy | 33 | 2017-12-11actual | — | 2018-02-22 |
| Retrospective Chart Review Study of Korlym for the Treatment of ACTH Independent Cushing's SyndromeNCT02663609observationalDrug Utilization Patterns as assessed by chart review | — | Completed | Other: No intervention | Cushing's Syndrome | 24 | 2017-12-01actual | — | 2023-06-01 |
| Crossover Drug-Drug Interaction Study to Determine Effects of Cytochrome P450 3A on Exposure to Mifepristone and Its MetabolitesNCT03258372Cmax of mifepristone of period 1 vs Cmax of mifepristone of period 3Non-randomized · Open-label · Other | Phase 1 | Completed | Drug: Mifepristone | Healthy | 48 | 2017-11-29actual | — | 2018-02-23 |
| A Study to Evaluate the Pharmacokinetics of the Current Capsule Formulation of CORT125134 in Healthy SubjectsNCT06094790Area under the concentration-time curve over a dose-interval of plasma CORT125134 (AUCtau)Randomized · Open-label · Other | Phase 1 | Completed | Drug: CORT125134 150 mg, CORT125134 250 mg, CORT125134 dose to be determined | Healthy | 32 | 2017-11-15actual | — | 2023-10-23 |
| Mifepristone in Children With Refractory Cushing's DiseaseNCT01925092Adverse eventsOpen-label · Treatment | Phase 3 | Withdrawnsponsor's stated reason: Lack of enrollment | Drug: mifepristone | Cushing's Disease | 0 | Dec 2016 | — | 2014-08-04 |
| A Study Designed to See How [14C]-CORT125134 is Taken up, Broken Down and Removed From the BodyNCT03067376Amount of radioactivity eliminated in urineOpen-label · Basic science | Phase 1 | Completed | Drug: [14C]-CORT125134 | Healthy | 9 | Sep 2016actual | — | 2019-08-09 |
| A Study to Evaluate the Pharmacokinetics of the CORT125134 Phase 2 Formulation in Healthy Male SubjectsNCT06094712Maximum concentration of plasma CORT125134 (Cmax)Open-label · Other | Phase 1 | Completed | Drug: CORT125134 | Healthy | 8 | 2016-04-27actual | — | 2023-10-23 |
| CORT125134 Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD)NCT03508635Incidence of Treatment-Emergent Adverse Events (AEs) (Safety and Tolerability) of CORT125134Randomized · Double-masked · Basic science | Phase 1 | Completed | Drug: CORT125134, Matching Placebo of CORT125134, Mifepristone, Prednisone, Glucose | Healthy | 130 | Dec 2015actual | — | 2019-08-09 |
| A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic FeaturesNCT00637494results2017-02-16Proportion of Mifepristone vs. Placebo Treated Patients With at Least a 50% Reduction From Baseline in Brief Psychiatric Rating Scale-Positive Symptom Subscale (BPRS-PSS) at Days 7 and 56Randomized · Quadruple-masked · Treatment | Phase 3 | Terminatedsponsor's stated reason: DRC recommended stopping study as it had missed its primary endpoint | Drug: mifepristone, placebo | Psychotic Depression, Severe Major Depression With Psychotic Features, Psychosis | 292 | Jun 2014actual | — | 2017-06-05 |
| An Extension Study of CORLUX in the Treatment of Endogenous Cushing's SyndromeNCT00936741results2014-04-02Number of Participants With Adverse EventsOpen-label · Treatment | Phase 3 | Completed | Drug: mifepristone | Cushing's Syndrome | 30 | Sep 2012actual | — | 2014-04-02 |
| Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's SyndromeNCT01371565results2013-11-20Number of Participants With Adverse EventsOpen-label · Treatment | Phase 3 | Completed | Drug: Mifepristone | Cushing's Disease, Cushing's Syndrome | 4 | Jun 2012actual | — | 2014-03-18 |
| A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's SyndromeNCT00569582results2012-05-28Improvement in Diabetes and/or Glucose Intolerance.Open-label · Treatment | Phase 3 | Completed | Drug: mifepristone | Cushing's Syndrome | 50 | Jan 2011actual | — | 2013-08-22 |
| A Study to Confirm Recurrent or Persistent Cushing's Syndrome in Patients With Signs or Symptoms of HypercortisolemiaNCT00796783observationalTo confirm the presence of recurrent or persistent endogenous Cushing's syndrome in patients who have had primary surgical and/or radiation therapy for Cushing's disease and continue to manifest symptoms and signs of hypercortisolemia. | — | Terminated | Drug: Cushing's syndrome confirmation | Cushing's Syndrome | 2 | Jun 2010actual | — | 2014-06-20 |
| A 4-week Study of Mifepristone in the Prevention of Risperidone-induced Weight Gain in Healthy Male VolunteersNCT00698022results2012-05-04Change From Baseline in Body WeightRandomized · Triple-masked · Prevention | Phase 1 | Completed | Drug: Risperidone, Mifepristone, Risperidone-matched placebo, Mifepristone-matched placebo | Healthy | 76 | Feb 2009actual | — | 2022-02-08 |
| A Phase I Study to Determine the Effect of Mifepristone on the Pharmacokinetics of Fluvastatin in Healthy VolunteersNCT00752843To determine the effect of single and multiple oral doses of CORLUX on the pharmacokinetics of a single oral dose of fluvastatin administered to healthy volunteers.Open-label · Basic science | Phase 1 | Completed | Drug: mifepristone + fluvastatin | Healthy Subjects | 20 | Nov 2008actual | — | 2012-02-17 |
| A United States Study of the Safety and Tolerability of Corlux for Psychotic Symptoms in Psychotic Major DepressionNCT00128479The change in a measure of psychosisRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: mifepristone, mifepristone matched placebo, mifepristone 600 mg, mifepristone 1200 mg | Major Depressive Disorder, Psychotic Disorders | 443 | Jan 2007actual | — | 2012-02-15 |
| An International Extension Study of Corlux for Recurrent Psychotic Symptoms in Psychotic Major DepressionNCT00128505To evaluate the safety and tolerability of Corlux (mifepristone) for the treatment of recurrent psychotic symptoms with major depression with psychotic features (PMD) who previously participated in Corcept Therapeutics Protocol C-1073-09Open-label · Treatment | Phase 3 | Completed | Drug: Mifepristone | Major Depressive Disorder, Psychotic Disorders | 104 | Nov 2006actual | — | 2012-02-15 |
| A United States Extension Study of Corlux for Recurrent Psychotic Symptoms in Psychotic Major DepressionNCT00208156To evaluate the safety and tolerability of Corlux (mifepristone) for the treatment of recurrent psychotic symptoms with major depression with psychotic features (PMD) who previously participated in Corcept Therapeutics Protocol C-1073-07Open-label · Treatment | Phase 3 | Completed | Drug: Mifepristone | Depressive Disorder, Major | 87 | Nov 2006actual | — | 2012-02-15 |
| An International Study of the Safety and Tolerability of Corlux for Psychotic Symptoms in Psychotic Major DepressionNCT00146523The change in a measure of psychosisRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Mifepristone, placebo | Major Depressive Disorder | 247 | Jul 2006actual | — | 2012-02-15 |
| A United States Study of Corlux for Psychotic Symptoms in Psychotic Major DepressionNCT00130676The change in a measure of psychosisRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Mifepristone, matching placebo | Major Depressive Disorder, Psychotic Disorders | 257 | Jun 2006actual | — | 2012-02-15 |
| Mifepristone as Adjunctive Therapy in Alzheimer's DiseaseNCT00105105effects on cognitionRandomized · Double-masked · Treatment | Phase 2 | Terminated | Drug: Mifepristone | Alzheimer's Disease | 160 | Nov 2005actual | — | 2009-12-11 |
| A Two-Week Study of the Efficacy and Safety of Mifepristone in the Prevention of Olanzapine-Induced Weight GainNCT00455442To determine the efficacy of mifepristone in the prevention of olanzapine-induced weight gain in healthy male volunteers.Randomized · Double-masked | Phase 2 | Completed | Drug: Mifepristone | Weight-Gain Prevention | 57 | — | — | 2008-09-19 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19